https://pharmato.ai/blog/innovent-biologics-cldn182-adc-ibi343-meets-primary-endpoint-in-phase-3-trial
Innovent Biologics' CLDN18.2 ADC IBI343 Meets Primary Endpoint in Phase 3 Trial
Jun 5, 2026 - On June 4, 2026, Innovent Biologics, Inc. announced that its innovative Claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC), IBI343 (arcotatug tavatecan), has...
innovent biologicsprimary endpointadcmeetsphase